Psyence Biomedical Ltd (PBM)

$3.80 -0.20 (-5.09%)
Market Cap 655,000.00
Revenue (ttm) 0.00
Net Income (ttm) 1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,069,700
Avg Vol 387,661
Day's Range N/A - N/A
Shares Out 1.02M
Stochastic %K 2%
Beta 0.32
Analysts Strong Buy
Price Target N/A

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 346 7764
Address:
121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada
dave450
dave450 Feb. 3 at 3:02 PM
$PBM Dropped more after my last post, damn
0 · Reply
dave450
dave450 Feb. 3 at 2:49 PM
$PBM PBM ultra low float, Lets go
0 · Reply
MillionaireTrader555
MillionaireTrader555 Feb. 3 at 2:33 PM
$EDBL will make a $PBM move like yesterday! Has a better share structure also!
0 · Reply
frankyboyz
frankyboyz Feb. 3 at 2:33 PM
$EDBL $PBM Halt up $EDBL
1 · Reply
gmcdade
gmcdade Feb. 3 at 2:29 PM
$PBM lets go!
0 · Reply
Dreamer89
Dreamer89 Feb. 3 at 2:15 PM
$EDBL Rs today come on pamp it like $PBM yesterday so I can dump on degen heads later. Let's gooooo. 👍
0 · Reply
dpdlwnl12
dpdlwnl12 Feb. 3 at 2:13 PM
$PBM $20++
0 · Reply
frankyboyz
frankyboyz Feb. 3 at 2:11 PM
$EDBL gimme those $PBM vibes 😁
0 · Reply
gmcdade
gmcdade Feb. 3 at 1:43 PM
$PBM
0 · Reply
SOLMOON
SOLMOON Feb. 3 at 1:08 PM
$NPT $PBM
0 · Reply
Latest News on PBM
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 28, 2026, 6:30 PM EST - 5 days ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 22, 2026, 1:42 PM EST - 11 days ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 20, 2026, 7:19 AM EST - 14 days ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 12, 2026, 8:30 AM EST - 22 days ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Jan 5, 2026, 9:15 AM EST - 4 weeks ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 19, 2025, 7:00 AM EST - 6 weeks ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Dec 9, 2025, 7:00 AM EST - 2 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 25, 2025, 7:00 AM EST - 2 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 20, 2025, 7:00 AM EST - 2 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 12, 2025, 7:00 AM EST - 2 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 6, 2025, 7:00 AM EST - 3 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Nov 3, 2025, 7:00 AM EST - 3 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Aug 28, 2025, 8:00 AM EDT - 5 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 25, 2025, 5:00 PM EDT - 7 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 8 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 18, 2025, 8:30 AM EDT - 8 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Jun 17, 2025, 8:00 AM EDT - 8 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025, 7:30 AM EDT - 9 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025, 7:30 AM EDT - 9 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 7:17 PM EDT - 10 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

Apr 17, 2025, 9:39 AM EDT - 10 months ago

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 15, 2025, 8:30 AM EDT - 10 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Apr 8, 2025, 8:00 AM EDT - 10 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 18, 2025, 8:30 AM EDT - 11 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Mar 10, 2025, 11:18 AM EDT - 11 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Sep 19, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 18, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 16, 2024, 9:31 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Sep 13, 2024, 4:30 PM EDT - 1 year ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

dave450
dave450 Feb. 3 at 3:02 PM
$PBM Dropped more after my last post, damn
0 · Reply
dave450
dave450 Feb. 3 at 2:49 PM
$PBM PBM ultra low float, Lets go
0 · Reply
MillionaireTrader555
MillionaireTrader555 Feb. 3 at 2:33 PM
$EDBL will make a $PBM move like yesterday! Has a better share structure also!
0 · Reply
frankyboyz
frankyboyz Feb. 3 at 2:33 PM
$EDBL $PBM Halt up $EDBL
1 · Reply
gmcdade
gmcdade Feb. 3 at 2:29 PM
$PBM lets go!
0 · Reply
Dreamer89
Dreamer89 Feb. 3 at 2:15 PM
$EDBL Rs today come on pamp it like $PBM yesterday so I can dump on degen heads later. Let's gooooo. 👍
0 · Reply
dpdlwnl12
dpdlwnl12 Feb. 3 at 2:13 PM
$PBM $20++
0 · Reply
frankyboyz
frankyboyz Feb. 3 at 2:11 PM
$EDBL gimme those $PBM vibes 😁
0 · Reply
gmcdade
gmcdade Feb. 3 at 1:43 PM
$PBM
0 · Reply
SOLMOON
SOLMOON Feb. 3 at 1:08 PM
$NPT $PBM
0 · Reply
Rampageusa
Rampageusa Feb. 3 at 12:44 PM
$PBM day 2 run. Stronger than day 1?? 6:1 R/S In effect makes it microfloater 180k..? 20$ pt on Squueze
1 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 11:58 AM
$RAYA 7/8am potential here bulls No walls could spike fast with a 800k float Why chase when you could be early $FATN $SIDU $PBM
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 11:33 AM
$RAYA Basically fee slaps here and shes gone Reminds me allot of $CDT $PBM
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 11:23 AM
$RAYA $PBM $CDT Raya heating up 🔥⏰️
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 11:02 AM
$RAYA potential next low floto pull a $PBM $CDT move Heavy shorted low floater looks primed ⏰️🔥
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 10:47 AM
$RAYA 7/8am potential crazy oversold 800k floater basically bottom play Low risk high reward at this price We saw what $PBM $CDT did 1.40$ break Raya gets it going Be early
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 10:44 AM
$RAYA 7/8am potential crazy oversold 800k floater basically bottom play Low risk high reward at this price We saw what $PBM $JLHL did yesterday 🔥
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 10:22 AM
$RAYA 800k floater crazy setup Way to cheap here Could be next to go like $XTKG $PBM $SXTC China low floater absolute bottom here Above 1.45 this goes hard
0 · Reply
MoneyFrogy
MoneyFrogy Feb. 3 at 10:19 AM
$RAYA Adding here crazy cheap low floater Reminds me of $JLHL $PBM
0 · Reply
RuddyRolls
RuddyRolls Feb. 3 at 9:20 AM
$PBM loaded the boat again.
1 · Reply
tainuibull
tainuibull Feb. 3 at 9:14 AM
$PBM round 2 buy the dip
0 · Reply
issi62
issi62 Feb. 3 at 9:07 AM
$PBM looks like they are going to bury this to death...
0 · Reply